MHY5396 treatment significantly reduced the expression of inflammation‐related genes (Ccl2, Ccl5, and Cxcl1) and macrophage markers (Emr1 and Cd163) compared with the FA group (Figure 7A,B). The gene discussed is CD163; the disease is Friedreich ataxia.